KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $85.6 million.

  • Castle Biosciences' Cash & Equivalents fell 989.47% to $85.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.6 million, marking a year-over-year decrease of 989.47%. This contributed to the annual value of $119.7 million for FY2024, which is 2111.27% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Cash & Equivalents is $85.6 million, which was down 989.47% from $82.2 million recorded in Q2 2025.
  • Castle Biosciences' Cash & Equivalents' 5-year high stood at $407.0 million during Q1 2021, with a 5-year trough of $82.2 million in Q2 2025.
  • Its 5-year average for Cash & Equivalents is $176.3 million, with a median of $114.8 million in 2023.
  • Per our database at Business Quant, Castle Biosciences' Cash & Equivalents skyrocketed by 31253.79% in 2021 and then crashed by 6489.31% in 2023.
  • Over the past 5 years, Castle Biosciences' Cash & Equivalents (Quarter) stood at $329.6 million in 2021, then tumbled by 62.7% to $122.9 million in 2022, then decreased by 19.61% to $98.8 million in 2023, then rose by 21.11% to $119.7 million in 2024, then dropped by 28.49% to $85.6 million in 2025.
  • Its Cash & Equivalents stands at $85.6 million for Q3 2025, versus $82.2 million for Q2 2025 and $89.7 million for Q1 2025.